Rep. Maria Elvira Salazar Unloads Shares of Moderna, Inc. (NASDAQ:MRNA)

Representative Maria Elvira Salazar (Republican-Florida) recently sold shares of Moderna, Inc. (NASDAQ:MRNA). In a filing disclosed on October 7th, the Representative disclosed that they had sold between $1,001 and $15,000 in Moderna stock on September 24th. The trade occurred in the Representative’s “UBS IRA ACCOUNT” account.

Representative Maria Elvira Salazar also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Citigroup (NYSE:C) on 9/24/2026.
• Sold $1,001 – $15,000 in shares of Chubb (NYSE:CB) on 9/24/2026.
• Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 9/24/2026.
• Sold $1,001 – $15,000 in shares of GE Aerospace (NYSE:GE) on 9/24/2026.
• Sold $1,001 – $15,000 in shares of Honeywell International (NASDAQ:HON) on 9/24/2026.
• Sold $1,001 – $15,000 in shares of Snowflake (NYSE:SNOW) on 9/24/2026.
• Sold $1,001 – $15,000 in shares of FedEx (NYSE:FDX) on 9/24/2026.
• Sold $1,001 – $15,000 in shares of Salesforce (NYSE:CRM) on 9/24/2026.
• Sold $1,001 – $15,000 in shares of RH (NYSE:RH) on 9/24/2026.
• Sold $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 9/24/2026.

Moderna Stock Performance

Shares of NASDAQ:MRNA opened at $197.00 on Friday. The firm’s 50 day simple moving average is $136.67 and its 200 day simple moving average is $83.94. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18. The company has a market capitalization of $78.65 billion, a price-to-earnings ratio of -24.66 and a beta of 1.09. Moderna, Inc. has a fifty-two week low of $22.28 and a fifty-two week high of $212.22.

Moderna (NASDAQ:MRNA) last announced its earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, topping the consensus estimate of ($2.03) by $0.06. The firm had revenue of $145.00 million for the quarter, compared to the consensus estimate of $102.93 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The business’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same period in the previous year, the business earned ($2.13) EPS. As a group, sell-side analysts forecast that Moderna, Inc. will post -6.09 earnings per share for the current year.

Insider Buying and Selling at Moderna

In other Moderna news, insider Shannon Klinger sold 3,471 shares of Moderna stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total value of $485,766.45. Following the sale, the insider owned 74,129 shares of the company’s stock, valued at approximately $10,374,353.55. The trade was a 4.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO James M. Mock sold 34,836 shares of the firm’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the transaction, the chief financial officer directly owned 59,375 shares of the company’s stock, valued at approximately $7,985,343.75. This trade represents a 36.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 118,882 shares of company stock worth $16,862,280 in the last ninety days. 10.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Moderna

Several hedge funds and other institutional investors have recently modified their holdings of MRNA. Allied Private Wealth LLC acquired a new stake in shares of Moderna in the second quarter valued at approximately $30,000. Canton Hathaway LLC acquired a new stake in shares of Moderna in the 1st quarter worth $31,000. Archer Investment Corp acquired a new position in shares of Moderna during the 2nd quarter valued at about $36,000. Assetmark Inc. grew its holdings in shares of Moderna by 35.1% in the first quarter. Assetmark Inc. now owns 801 shares of the company’s stock valued at $41,000 after purchasing an additional 208 shares during the period. Finally, Frazier Financial Advisors LLC acquired a new stake in Moderna during the second quarter worth about $45,000. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna News Summary

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Nasdaq-100 inclusion may create additional demand. Moderna’s entry into the index follows a reported 566% stock surge and could prompt buying by index-tracking funds. The move also increases the company’s visibility among institutional investors. Moderna’s Nasdaq-100 Entry: What Does It Mean for the Stock?
• Positive Sentiment: Progress in personalized cancer vaccines is strengthening Moderna’s post-COVID growth story. Moderna and Merck expanded a multi-year collaboration with Tempus to support potential commercialization of intismeran autogene (V940/mRNA-4157), an individualized neoantigen therapy being studied with Keytruda in melanoma and other cancers. A successful oncology franchise could diversify revenue beyond COVID vaccines. Tempus Announces Multi-Year Collaboration with Moderna and Merck
• Positive Sentiment: Manufacturing and technology developments are providing additional pipeline optimism. Moderna is applying lessons from its COVID-era production network to scale cancer therapies, while experimental AI research could eventually reduce cold-storage requirements for mRNA vaccines and improve distribution economics. Experimental approach uses AI to eliminate cold storage for mRNA vaccines
• Neutral Sentiment: Moderna’s broader pipeline of mRNA vaccines and oncology treatments is attracting investor interest, but many programs remain dependent on clinical, regulatory and commercial execution. Axsome Therapeutics vs. Moderna
• Negative Sentiment: Morgan Stanley maintained a cautious view. The firm rated Moderna “Equal Weight” or “Hold” and raised its price target only from $89 to $95, far below the recent trading level. That gap suggests the analyst believes expectations and valuation may be excessive. Moderna Gets a Hold from Morgan Stanley
• Negative Sentiment: Commentary warning that Moderna could be materially above fair value, combined with ongoing losses and the challenge of manufacturing individualized cancer treatments at scale, creates downside risk if clinical or commercial milestones disappoint. Moderna Could Be Above Fair Value

Wall Street Analysts Forecast Growth

MRNA has been the topic of several analyst reports. Barclays upped their target price on shares of Moderna from $48.00 to $125.00 and gave the stock an “equal weight” rating in a research note on Monday, August 24th. Rothschild & Co Redburn downgraded Moderna from a “neutral” rating to a “sell” rating and raised their price objective for the stock from $40.00 to $81.00 in a research note on Thursday, September 3rd. Loop Capital set a $135.00 target price on shares of Moderna in a research note on Wednesday, August 19th. Piper Sandler restated an “overweight” rating on shares of Moderna in a research note on Monday, August 3rd. Finally, William Blair assumed coverage on Moderna in a research note on Friday, August 28th. They set an “outperform” rating for the company. Seven investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and five have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $78.17.

About Representative Salazar

Maria Elvira Salazar (Republican Party) is a member of the U.S. House, representing Florida’s 27th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.

Salazar (Republican Party) ran for re-election to the U.S. House to represent Florida’s 27th Congressional District. She won in the general election on November 5, 2024.

Maria Elvira Salazar was born in Miami, Florida, and lives in Coral Gables, Florida. Salazar earned an undergraduate degree from the University of Miami in 1983 and a graduate degree from Harvard University in 1995. Her career experience includes working as a television journalist, reporter, and news anchor.

Moderna Company Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease, supporting the company’s work across infectious diseases, immuno-oncology, rare diseases, autoimmune conditions, and cardiovascular diseases.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.